Key result
Bioprosthetic venous valve yields clinically meaningful rVCSS improvement in ~85% of patients at one year.
Why the study?
Traditional treatments for chronic venous insufficiency have focused on symptom management or superficial veins, lacking effective therapies addressing deep venous valve failure and reflux.
Does bioprosthetic venous valve implantation improve clinical severity and quality of life in patients with severe chronic venous insufficiency unresponsive to standard of care?
Population
75 patients with severe chronic venous insufficiency (CEAP C4b, C4c, C5, C6) unresponsive to standard therapy
Comparison
Bioprosthetic venous valve implantation (VenoValve) with no comparator group
Design
Prospective, single-arm, multicenter study
Follow-up
12 months
Authors
Loading...
Bioprosthetic valve implantation may improve outcomes in deep venous CVI; leaves open efficacy and safety pending randomized trials.
Does bioprosthetic venous valve implantation improve clinical severity and quality of life in patients with severe chronic venous insufficiency unresponsive to standard of care?
Implantation of a bioprosthetic venous valve in patients with severe chronic venous insufficiency unresponsive to standard care resulted in significant clinical and quality of life improvements at 1 year.
Chaar et al. (2025) studied severe chronic venous insufficiency (n=75). Bioprosthetic venous valve device (VenoValve) was evaluated on Clinically meaningful improvement (decrease in rVCSS of at least 3 points). Implantation of a bioprosthetic venous valve resulted in 84.6% of patients achieving clinically meaningful improvement in rVCSS at 12 months, with an average improvement of 7.9 points.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: